Results indicated that FDX1 may contribute to cisplatin resistance in ovarian cancer cells by inhibiting the increase in mitochondrial membrane potential and cisplatin-induced lipid peroxidation. This evidence concerns the gene FDX1 and ovarian carcinoma.